| Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label … C Moreno, R Greil, F Demirkan, A Tedeschi, B Anz, L Larratt, M Simkovic, ... The Lancet Oncology 20 (1), 43-56, 2019 | 625 | 2019 |
| ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia P Ghia, A Pluta, M Wach, D Lysak, T Kozak, M Simkovic, P Kaplan, ... Journal of Clinical Oncology 38 (25), 2849-2861, 2020 | 355 | 2020 |
| COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ... Leukemia 34 (9), 2354-2363, 2020 | 264 | 2020 |
| Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia JR Brown, B Eichhorst, P Hillmen, W Jurczak, M Kaźmierczak, ... New England Journal of Medicine 388 (4), 319-332, 2023 | 242 | 2023 |
| Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial CS Tam, JR Brown, BS Kahl, P Ghia, K Giannopoulos, W Jurczak, ... The Lancet Oncology 23 (8), 1031-1043, 2022 | 153 | 2022 |
| Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities AP Kater, C Owen, C Moreno, G Follows, T Munir, MD Levin, O Benjamini, ... NEJM evidence 1 (7), EVIDoa2200006, 2022 | 127 | 2022 |
| Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion CS Tam, T Robak, P Ghia, BS Kahl, P Walker, W Janowski, D Simpson, ... Haematologica 106 (9), 2354, 2021 | 100 | 2021 |
| First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia … P Hillmen, B Eichhorst, JR Brown, N Lamanna, S O’Brien, CS Tam, L Qiu, ... Proceedings of the 2021 European hematology association virtual congress 11, 2021 | 92 | 2021 |
| First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III … C Moreno, R Greil, F Demirkan, A Tedeschi, B Anz, L Larratt, M Simkovic, ... Haematologica 107 (9), 2108, 2022 | 87 | 2022 |
| COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study T Chatzikonstantinou, A Kapetanakis, L Scarfò, G Karakatsoulis, D Allsup, ... Leukemia 35 (12), 3444-3454, 2021 | 82 | 2021 |
| Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial P Hillmen, B Eichhorst, JR Brown, N Lamanna, SM O'Brien, CS Tam, ... Journal of Clinical Oncology 41 (5), 1035-1045, 2023 | 49 | 2023 |
| Acalabrutinib versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia: final ASCEND trial results P Ghia, A Pluta, M Wach, D Lysak, M Šimkovič, I Kriachok, Á Illés, ... Hemasphere 6 (12), e801, 2022 | 48 | 2022 |
| SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine+ rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small … CS Tam, K Giannopoulos, W Jurczak, M Šimkovič, M Shadman, ... Blood 138, 396, 2021 | 40 | 2021 |
| Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del (17p): initial results from … CS Tam, T Robak, P Ghia, BS Kahl, P Walker, W Janowski, D Simpson, ... Blood 134, 499, 2019 | 38 | 2019 |
| Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia L Smolej, M Doubek, A Panovská, M Šimkovič, Y Brychtová, D Belada, ... Leukemia Research 36 (10), 1278-1282, 2012 | 35 | 2012 |
| Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen MC Thompson, RA Harrup, CC Coombs, LE Roeker, JJ Pu, MY Choi, ... Blood advances 6 (15), 4553-4557, 2022 | 31 | 2022 |
| First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+ Ven) versus chlorambucil plus obinutuzumab (Clb+ O) for … T Munir, C Moreno, C Owen, GA Follows, O Benjamini, A Janssens, ... Blood 138, 70, 2021 | 31 | 2021 |
| Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (Ibr+ Ven) versus chlorambucil plus … CU Niemann, T Munir, C Moreno, C Owen, GA Follows, O Benjamini, ... Blood 140 (Supplement 1), 228-230, 2022 | 28 | 2022 |
| Alternating R‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma P Klener, E Fronkova, D Belada, K Forsterova, R Pytlik, M Kalinova, ... Hematological Oncology 36 (1), 110-115, 2018 | 28 | 2018 |
| Low-dose FCR is a safe and effective treatment option for elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Updated results of project Q … L Smolej, Y Brychtova, M Doubek, E Cmunt, M Spacek, D Belada, ... Blood 124 (21), 4670, 2014 | 28 | 2014 |
